Performance Evaluation of TB Breath- and Cough-testing Platforms
Performance Evaluation of TB Breath- and Cough-testing Platforms
This will be a prospective, multicentre study conducted to evaluate the diagnostic accuracy
 of two TB breath-based technologies independently of the manufacturers. Assay error and
 failure rates and device operational characteristics will also be assessed during this study.
 Participants will be enrolled in this study in line with FIND sample banking activities.
 Results from index tests will not be used to make clinical decisions. Participation in this
 study will not alter the standard of care.
Inclusion Criteria:

 -  Symptoms suggesting pulmonary TB, i.e. persistent cough (generally > 3 weeks or as per
 local definition of TB suspect) and at least one other finding listed below:

 1. Persistent cough

 2. Fever

 3. Malaise

 4. Recent weight loss

 5. Night sweats

 6. Contact w/ active case

 7. Hemoptysis

 8. Chest pain

 9. Loss of appetite

 10. Other [specify]

 -  Provision of informed consent to sample collection, banking and HIV and breath-based
 assay testing

 -  Production of adequate quantity of sputum (sputum induction whenever possible)

 -  Adult age (>18 years old)

 Exclusion Criteria:

 -  Participants receiving any anti-tuberculosis medication, including fluoroquinolone and
 aminoglycosides in the 60 days prior to enrolment.

 -  Participants with ONLY extra-pulmonary disease will be excluded.

 -  Participants for whom complete follow-up and a clear final diagnosis are judged to be
 difficult (e.g. residents elsewhere or about to move).